3,743 results match your criteria Systemic Lupus Erythematosus and Pregnancy

Association of clinic setting with quality indicator performance in systemic lupus erythematosus: a cross-sectional study.

Arthritis Res Ther 2022 Jun 22;24(1):150. Epub 2022 Jun 22.

Monash University, Melbourne, Australia.

Background: Healthcare quality for systemic lupus erythematosus (SLE) is a modifiable target for improving patient outcomes. We aimed to assess the quality of care processes in different clinic settings, comparing a subspecialty lupus clinic with hospital-based and private general rheumatology clinics.

Methods: Patients with SLE (n = 258) were recruited in 2016 from a subspecialty lupus clinic (n = 147), two hospital general rheumatology clinics (n = 56) and two private rheumatology clinics (n = 55). Read More

View Article and Full-Text PDF

Systemic lupus erythematosus dysregulates the expression of long noncoding RNAs in placentas.

Arthritis Res Ther 2022 Jun 14;24(1):142. Epub 2022 Jun 14.

Department of Obstetrics and Gynecology, University of Wisconsin-Madison, Madison, WI, 53715, USA.

Background: Systemic lupus erythematosus (SLE) can cause placental dysfunctions, which may result in pregnancy complications. Long noncoding RNAs (lncRNAs) are actively involved in the regulation of immune responses during pregnancy. The present study aimed to determine the lncRNA expression profiles in placentas from women with SLE to gain new insights into the underlying molecular mechanisms in SLE pregnancies. Read More

View Article and Full-Text PDF

Impact of low-dose acetylsalicylic acid on pregnancy outcome in systemic lupus erythematosus: results from a multicentre study.

Lupus Sci Med 2022 06;9(1)

Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana and Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

Objective: It is still a matter of debate whether low-dose acetylsalicylic acid (LDASA) should be prescribed to all patients with SLE during pregnancy. This study aimed at investigating the impact of LDASA on pregnancy outcomes in patients with SLE without history of renal involvement and without antiphospholipid antibodies (aPL).

Methods: This is a retrospective analysis of prospectively monitored pregnancies at seven rheumatology centres. Read More

View Article and Full-Text PDF

Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ('Registry').

Lupus Sci Med 2022 06;9(1)

Rheumatology, Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, New York, USA

Objectives: To describe the outcomes of pregnancies in antiphospholipid antibody (aPL)-positive patients since the inception of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Registry.

Methods: We identified persistently aPL-positive patients recorded as 'pregnant' during prospective follow-up, and defined as a composite of: (1) Preterm live delivery (PTLD) at or before 37th week due to pre-eclampsia (PEC), eclampsia, small-for-gestational age (SGA) and/or placental insufficiency (PI); or (2) Otherwise unexplained fetal death after the 10th week of gestation. The primary objective was to describe the characteristics of patients with and without aPL-related composite outcomes based on their first observed pregnancies following registry recruitment. Read More

View Article and Full-Text PDF

Clinical characteristics and prognosis of patients with antiphospholipid antibodies based on cluster analysis: an 8-year cohort study.

Arthritis Res Ther 2022 Jun 11;24(1):140. Epub 2022 Jun 11.

Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Background: Antiphospholipid syndrome (APS) is an autoimmune disease characterized by persistent antiphospholipid antibodies (aPLs) positivity with a wide manifestation spectrum. A risk stratification is needed for management guidance and prognosis assessment. We aimed to identify phenotypes among aPL-positive patients and assess the prognosis of each phenotype. Read More

View Article and Full-Text PDF

Improved pregnancy outcomes in systemic lupus erythematosus: A retrospective study of pregnancies from a single centre in Denmark from 2010-2020 compared with the period 1990-2010.

Lupus 2022 Jun 8:9612033221107538. Epub 2022 Jun 8.

Department of Rheumatology, 11297Aarhus University Hospital, Aarhus, Denmark.

Objectives: Over the past decades new international guidelines recommend that pregnant Systemic lupus erythematosus (SLE) patients are monitored closely in a multi-professional team throughout pregnancy. The importance of low disease activity before pregnancy and continued treatment during pregnancy has been established. However, there is still a high risk of adverse pregnancy outcome (APO). Read More

View Article and Full-Text PDF

Systemic Lupus Erythematosus Delivery Outcomes Are Unchanged Across Three Decades.

ACR Open Rheumatol 2022 Jun 6. Epub 2022 Jun 6.

Vanderbilt University Medical Center, Nashville, Tennessee.

Objective: Using a large, de-identified electronic health record database with over 3.2 million patients, we aimed to identify trends of systemic lupus erythematosus (SLE) medication use during pregnancy and birth outcomes from 1989 to 2020.

Methods: Using a previously validated algorithm for SLE deliveries, we identified 255 pregnancies in patients with SLE and 604 pregnancies in controls with no known autoimmune diseases. Read More

View Article and Full-Text PDF

Current Recommendations for the Systemic Treatment of Cutaneous Lupus Erythematosus During Pregnancy.

Cutis 2022 Feb;109(2):90-E1

Ms. Kirchner is from the Department of Dermatology, University of Illinois College of Medicine, Chicago. Drs. Riegert and Lake are from the Division of Dermatology, Stritch School of Medicine, Loyola University, Chicago.

Cutaneous lupus erythematosus (CLE) is a heterogeneous autoimmune disease of the skin that commonly affects women of childbearing age. Some of the medications used in the treatment of CLE are safe in pregnancy, whereas others are contraindicated based on their teratogenic effects. We describe the most recent recommendations for the use of commonly prescribed CLE medications for those who are pregnant or plan on becoming pregnant. Read More

View Article and Full-Text PDF
February 2022

An Indonesian pregnant woman with systemic lupus erythematosus and cardiac tamponade: A case report.

Int J Surg Case Rep 2022 May 4;94:107159. Epub 2022 May 4.

Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. Electronic address:

Background: Systemic lupus erythematosus (SLE) during pregnancy with cardiac tamponade is a rare case.

Case Presentation: A 33-year-old pregnant woman complained of worsening shortness of breath, hair loss, and joint pain. Laboratory investigation revealed the poor condition of the patient so therapeutic abortion was recommended. Read More

View Article and Full-Text PDF

Risk factors associated with infections in pregnant women with systemic lupus erythematosus.

Rev Assoc Med Bras (1992) 2022 Apr;68(4):536-541

Universidade do Estado do Rio de Janeiro - Rio de Janeiro (RJ), Brazil.

Objective: The aim of this study was to analyze the occurrence and risk factors associated with infections during pregnancy in patients with systemic lupus erythematosus.

Methods: This is a retrospective cohort study using the data of pregnant women who were followed up between 2011 and 2018 at a university hospital.

Results: The data of 221 pregnant women with systemic lupus erythematosus were analyzed. Read More

View Article and Full-Text PDF

High-risk twin pregnancy: case report of an adolescent patient with cystic fibrosis and systemic lupus erythematosus.

J Med Case Rep 2022 May 31;16(1):230. Epub 2022 May 31.

Hospital de Clínicas de Porto Alegre, Ramiro Barcelos 2350 /sala 1131, Porto Alegre, Brazil.

Background: We present the first case to our knowledge of a spontaneous twin pregnancy in a 16-year-old Caucasian patient with cystic fibrosis and systemic lupus erythematosus. Cystic fibrosis is one of the most common autosomal recessive genetic disorders and primarily affects the respiratory and digestive systems. Systemic lupus erythematosus is a chronic inflammatory disease of unknown cause that affects nearly every organ. Read More

View Article and Full-Text PDF

Effects of Astragalus membranaceus on systemic lupus erythematosus in a mouse model of pregnancy.

Immun Inflamm Dis 2022 Jun;10(6):e624

Department of Pharmacy, The Fourth Hospital of Shijiazhuang, Shijiazhuang, Hebei, China.

Background: This study used astragalus membranaceus (AM) to treat systemic lupus erythematosus (SLE) model mice during pregnancy, aiming to explore the role of AM in Helper T cell 17 (Th17) differentiation and SLE during pregnancy.

Methods: We used lipopolysaccharide to constructed the SLE mouse model. AM decoction given by intragastric administration lasted from the eighth week of the mouse age until the mouse was killed. Read More

View Article and Full-Text PDF

Factors associated with adverse pregnancy outcomes in patients with systemic lupus erythematosus.

Musculoskeletal Care 2022 May 26. Epub 2022 May 26.

Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain.

Background: Pregnancies in Systemic lupus erythematosus (SLE) are considered high risk and associated with maternal and obstetric complications.

Objectives: To determine the most important predictors for each of the main adverse pregnancy outcomes in SLE patients.

Methods: Patients with SLE were retrospectively analysed from 1990 to 2020. Read More

View Article and Full-Text PDF

Identifying Barriers to Enrollment in Patient Pregnancy Registries: Building Evidence Through Crowdsourcing.

JMIR Form Res 2022 May 25;6(5):e30573. Epub 2022 May 25.

Safety Innovation and Analytics, GlaxoSmithKline, Durham, NC, United States.

Background: Enrollment in pregnancy registries is challenging despite substantial awareness-raising activities, generally resulting in low recruitment owing to limited safety data. Understanding patient and physician awareness of and attitudes toward pregnancy registries is needed to facilitate enrollment. Crowdsourcing, in which services, ideas, or content are obtained by soliciting contributions from a large group of people using web-based platforms, has shown promise for improving patient engagement and obtaining patient insights. Read More

View Article and Full-Text PDF

Predictors of refractory risk in systemic lupus erythematosus-related thrombocytopenia: a dual-centre retrospective study.

Lupus Sci Med 2022 05;9(1)

Department of Clinical Epidemiology, The First Hospital of Jilin University, Changchun, China

Objectives: Based on clinical and laboratory indicators, this study aimed to establish a multiparametric nomogram to assess the risk of refractory cases of SLE-related thrombocytopenia (SLE-related TP) before systematic treatment.

Methods: From June 2012 to July 2021, a dual-centre retrospective cohort study of prospectively collected data of patients with SLE-related TP was conducted. The cohort data were divided into a developing set, internal validation set and external validation set. Read More

View Article and Full-Text PDF

Characteristics of childhood-onset systemic lupus erythematosus in pregnancy and its association with pregnancy outcomes: a retrospective comparative cohort study.

Reprod Biol Endocrinol 2022 May 19;20(1):78. Epub 2022 May 19.

Department of Epidemiology, School of Public Health, Southern Medical University, No.1846, North of Guangzhou Avenue, Guangzhou, 510515, Guangdong, China.

Background: Disease situations are more aggressive in patients with childhood-onset systemic lupus erythematosus (cSLE) than in those with adult-onset SLE (aSLE). However, information on pregnant women with cSLE and its association with pregnancy outcomes is limited. This study aimed to compare pregnancies in patients with cSLE vs. Read More

View Article and Full-Text PDF

Jagged Ends on Multinucleosomal Cell-Free DNA Serve as a Biomarker for Nuclease Activity and Systemic Lupus Erythematosus.

Clin Chem 2022 May 19. Epub 2022 May 19.

Centre for Novostics, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong SAR, China.

Background: Jagged ends of plasma DNA are a recently recognized class of fragmentomic markers for cell-free DNA, reflecting the activity of nucleases. A number of recent studies have also highlighted the importance of jagged ends in the context of pregnancy and oncology. However, knowledge regarding the generation of jagged ends is incomplete. Read More

View Article and Full-Text PDF

Increased microchimerism in peripheral blood of women with systemic lupus erythematosus: relation with pregnancy.

Clin Exp Rheumatol 2022 Apr 29. Epub 2022 Apr 29.

Department of Pathology, Leiden University Medical Center, Leiden, and Pathan B.V., Laboratory for Pathology, Rotterdam, The Netherlands.

Objectives: We aimed to determine the presence, amount and origin of microchimerism in peripheral blood of pregnant and non-pregnant parous women with systemic lupus erythematosus (SLE) as compared to control subjects.

Methods: We performed a comparative study in which peripheral blood was drawn from eleven female non-pregnant SLE-patients and 22 control subjects, and from six pregnant SLE-patients and eleven control subjects during gestation and up to six months postpartum. Quantitative PCR for insertion-deletion polymorphisms and null alleles was used to detect microchimerism in peripheral blood mononuclear cells and granulocytes. Read More

View Article and Full-Text PDF

The correlation between proteoglycan 2 and neuropsychiatric systemic lupus erythematosus.

Clin Immunol 2022 Jun 12;239:109042. Epub 2022 May 12.

The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Medical School, Nanjing University, Nanjing 210093, China; Jiangsu Key Laboratory of Molecular Medicine, Nanjing University, Nanjing 210093, China. Electronic address:

The proposed pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE) mainly includes ischemia and neuroinflammation mechanisms. Protein encoded by Proteoglycan 2 (PRG2) mRNA is involved in the immune process related to eosinophils, also being found in the placenta and peripheral blood of pregnant women. We evaluated the correlation between PRG2 and NPSLE for the first time and found that PRG2 protein was overexpressed in the serum of patients with NPSLE and correlated with the SLE disease activity index (SLEDAI) subset scores of psychosis. Read More

View Article and Full-Text PDF

The Impact of Preeclampsia in Lupus Nephritis.

Expert Rev Clin Immunol 2022 May 10:1-13. Epub 2022 May 10.

Independent Researcher, Past Director Nephrology Policlinico, Milan, Italy.

Introduction: Women with systemic lupus erythematosus (SLE), particularly those with lupus nephritis (LN), remain at high risk for adverse pregnancy outcome. Although in the last decades maternal and fetal outcomes have improved dramatically, preeclampsia remains a major cause of maternal and perinatal morbidity and mortality.

Areas Covered: A narrative review of literature was conducted, underlying the importance of pre-conception counseling, and focusing on the correlation between preeclampsia and LN. Read More

View Article and Full-Text PDF

Health Outcome of 215 Mothers of Children with Autoimmune Congenital Heart Block: Analysis of the French Neonatal Lupus Syndrome Registry.

J Rheumatol 2022 May 2. Epub 2022 May 2.

Cochin Hospital, Ile de France Rare Autoimmune and Systemic Diseases Reference Center, Paris, France; Reference Center for Complex Congénital Cardiac Malformations - M3C, Necker-Enfants Malades Hospital, Université from Paris, Paris, France; Obstetrics and maternal-fetal unit / APHP Hôpital Necker-Enfant Malades, Université from Paris, Paris, France; Department of Internal Medicine, CHU Nantes, France; Rare Autoimmune and Systemic Diseases Competence Center, Reims, France; Pitié-Salpêtrière Hospital, Reference Center for Rare Autoimmune and Systemic Diseases, Paris, France; Timone Children's Hospital, Unité of Pediatric Resuscitation, Marseille, France; Tenon Hospital, Paris, France; CHU Fort de France, Martinique, France; Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Systemic Autoimmune Diseases in the North and North-West of France (CeRAINO) , U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France; Cardiopédiatrics, University Hospital of Nantes, France; Cochin Hospital, Ile de France Rare Autoimmune and Systemic Diseases Reference Center, Paris, France; University Paris Descartes- Sorbonne Paris Cité, Paris, France; INSERM U 1153, Center for Epidemiology and Statistics Sorbonne Paris Cité (CRESS), Paris, France. Address for correspondence: Nathalie Costedoat-Chalumeau, Hôpital Cochin, 75014, Paris, France. Fax number: +33158413246. Phone number: +33687508123

Objective: Transplacental passage of maternal anti-SSA and -SSB antibodies, potentially associated with maternal autoimmune diseases, can cause neonatal lupus syndrome. Given the paucity of data in this setting, we report short- and long-term outcomes of mothers of offspring with congenital heart block (CHB).

Methods: This retrospective study included anti-SSA/SSB antibody-positive mothers of fetuses with high-degree CHB and focused on their health status before pregnancy, at CHB diagnosis, and thereafter. Read More

View Article and Full-Text PDF

Systemic sclerosis and pregnancy outcomes: a retrospective study from a single center.

Arthritis Res Ther 2022 04 27;24(1):91. Epub 2022 Apr 27.

Department of Autoimmune Diseases, Hospital Clinic, Universitat de Barcelona, Villarroel, 08036, Barcelona, Catalonia, Spain.

Background: Pregnancy in systemic sclerosis (SSc) patients is no more an infrequent event as it used to be, but literature data on pregnancy outcomes in women with SSc are scarce. The rate of preterm deliveries and intrauterine growth restriction (IUGR) seems to be increased, while the risk of miscarriages is controversial. Moreover, no study compared pregnancy outcomes in SSc with antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE). Read More

View Article and Full-Text PDF

The dynamics of Th17 / Treg ratio in SLE patients during pregnancy.

J Reprod Immunol 2022 Jun 8;151:103622. Epub 2022 Apr 8.

Instituto Ciências Biomédicas Abel Salazar, Oporto University, Oporto Portugal; Clinical Immunology Unit, Centro Hospitalar Universitário do Porto, Oporto, Portugal.

Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disorder that affects women at childbearing age. During pregnancy, maternal immune system is challenged to tolerate a semi-allogenic fetus and a shift toward a tolerogenic profile is essential. Failure to develop this tolerogenic profile seems to be associated with the development of adverse obstetric outcomes. Read More

View Article and Full-Text PDF

Uterine fibroids increase the risk of thyroid goiter and thyroid nodules.

Sci Rep 2022 04 22;12(1):6620. Epub 2022 Apr 22.

Department of Obstetrics and Gynecology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea.

Uterine fibroid and benign thyroid disease are both common diseases in women. This study aimed to evaluate whether these diseases are related. We established the uterine fibroid group according to diagnosis and surgery codes using the Korea National Health Insurance data from 2009 to 2020. Read More

View Article and Full-Text PDF

Tailored treatment strategies and future directions in systemic lupus erythematosus.

Rheumatol Int 2022 Apr 21. Epub 2022 Apr 21.

Rheumatology and Clinical Immunology, 4th Department of Internal Medicine, "Attikon" University Hospital, Medical School National and Kapodistrian University of Athens, Athens, Greece.

Systemic lupus erythematosus (SLE) represents a diagnostic and therapeutic challenge for physicians due to its protean manifestations and unpredictable course. The disease may manifest as multisystemic or organ-dominant and severity at presentation may vary according to age at onset (childhood-, adult- or late-onset SLE). Different manifestations may respond variably to different immunosuppressive medications and, even within the same organ-system, the severity of inflammation may vary from mild to organ-threatening. Read More

View Article and Full-Text PDF

Catastrophic Anti-Phospholipid Syndrome in Systemic Lupus Erythematosus: A Tsunami in the Ocean.

J Assoc Physicians India 2022 Apr;70(4):11-12

Armed Forces Medical College, Pune, Maharashtra; 2Command Hospital (Southern Command), Pune, Maharashtra.

Antiphospholipid anti body syndrome is an autoimmune disorder characterized by arterial or venous thrombosis and/or pregnancy morbidity with foetal deaths or abortions in the presence of antiphospholipid antibodies. Catastrophic antiphospholipid antibody syndrome (CAPS) is an accelerated form of disease with rapid involvement of multiple organ systems often posing a diagnostic challenge. There is a paucity of literature on the presentations of CAPS owing to the orphan nature of the disease. Read More

View Article and Full-Text PDF

Low pre-pregnant body mass index is a risk factor for the decrease of postpartum bone mineral density in systemic lupus erythematosus patients received glucocorticoid therapy.

Lupus 2022 Jun 19;31(7):848-854. Epub 2022 Apr 19.

Division of Rheumatology, Department of Internal Medicine (IV), 13010Osaka Medical and Pharmaceutical University Hospital, Osaka, Japan.

Objectives: This study investigated postpartum bone mineral density (BMD) in patients with systemic lupus erythematosus (SLE) receiving long-term glucocorticoid (GC) therapy, assessed risk factors for decreased postpartum BMD, and evaluated change of BMD after postpartum initiation or restarting of osteoporosis drugs.

Methods: We retrospectively examined 30 SLE patients who gave birth and 31 non-pregnant SLE patients. In the postpartum SLE patients, BMD was measured after delivery and 1 year later. Read More

View Article and Full-Text PDF

COVID-19 Mortality in Patients with Rheumatic Diseases: A Real Concern.

Curr Rheumatol Rev 2022 Apr 12. Epub 2022 Apr 12.

Infectious Diseases Unit, Royal Hospital, Muscat, Oman.

Background: Coronavirus disease 2019 (COVID 19) is a worldwide pandemic that has devastated the world in a way that has not been witnessed since the Spanish Flu in 1918. In this study, we aim to investigate the outcomes of patients with rheumatic diseases infected with COVID19 in Oman.

Methods: A multi-center retrospective cohort study included patients with underlying rheumatological conditions and COVID-19 infection. Read More

View Article and Full-Text PDF

Treatment with low-dose prednisone in refractory obstetric antiphospholipid syndrome: A retrospective cohort study and meta-analysis.

Lupus 2022 Jun 11;31(7):808-819. Epub 2022 Apr 11.

Rheumatology Department, 16516Hospital Universitario Marqués de Valdecilla, Santander, Spain.

Background: Glucocorticoids have been suggested as a potential therapy in refractory obstetric antiphospholipid syndrome (oAPS). Our aims were to describe a cohort of patients with oAPS treated with low-dose glucocorticoids and to perform a systematic review and meta-analysis evaluating the effects of additional glucocorticoids on the pregnancy outcomes in oAPS patients.

Methods: Retrospective study that included 11 women diagnosed with primary antiphospholipid syndrome. Read More

View Article and Full-Text PDF

Predictors Associated with Adverse Pregnancy Outcomes in a Cohort of Women with Systematic Lupus Erythematosus from Romania-An Observational Study (Stage 2).

J Clin Med 2022 Apr 1;11(7). Epub 2022 Apr 1.

Department of Obstetrics and Gynecology, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania.

Background: Pregnancy in women with systemic lupus erythematosus (SLE) is accompanied by adverse pregnancy outcomes (APOs). We aimed to investigate the association between clinical, sonographic, and laboratory parameters and APOs (preeclampsia, intrauterine growth restriction, premature birth, and maternal mortality).

Methods: This observational retrospective study included all pregnancies in women with SLE who attended two tertiary maternity hospitals from Romania between January 2013 and December 2020. Read More

View Article and Full-Text PDF